Is Spero Therapeutics Inc (SPRO) overvalued? · P/E 9.6, rev $48.0M
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
This page asks whether Spero Therapeutics Inc (SPRO) looks expensive on cached numbers — not a short thesis.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
SPRO currently screens at market cap $149.5M and trailing P/E 9.6. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next SPRO 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the SPRO stock page for the full model, not this heading.
Not investment advice.